Artgen

Artgen is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Artgen balance sheet

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Artgen cash flows

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Artgen multipliers

Report period2018 2019 2020 2021 2022 2023
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Artgen profitability

Report period2018 2019 2020 2021 2022 2023
ROA
ROE
ROS
EBITDA Margin
Operating margin
Artgen assets
Artgen cash flows
Artgen dividends
2.14%

Artgen dividend policy

The recommended amount of dividend payments is determined based on year-end financial results, economic situation, and industry position and may range from 40% to 60% of net profit.

Artgen shares

TickerNameTypeNominal valueISINPrice
ABIO:RMArtgenCommon shareRUB 0.1RU000A0JNAB6RUB 97.6

Artgen bonds

NameIssue sizePriceYield
ISKJ BO-01 (RUB)300,000 pcs.89.71%14.75%

Artgen expected events

DateTypeNoteSource
14.06.2024 10:00
Dividends
The last day of purchase for receiving dividends RUB 1.2 per common share for 2023.Pictogram of www.e-disclosure.ru  www.e-disclosure.ru
Share capital structure of Artgen
Artgen news
10.06.2024
Shareholders of Artgen approved dividends for 2023 in the amount of ₽1.2 per ordinary share. The last day of purchase of securities to receive dividends is June 14, 2024. Dividend yield may amount to 1.19%.
10.06.2024
Genotarget, a startup belonging to Artgen Biotech, has completed preclinical studies of a new gene therapy drug GTDF102 for the treatment of muscular dystrophy. In studies conducted on mice with a disease model, it was possible to achieve the synthesis of the normal protein dysferlin in an amount sufficient to improve the condition of muscle tissue. Genotarg...
Source: {source} pictogram artgen.ru
03.05.2024
Artgen's RAS net profit for 3 months of 2024 amounted to ₽68.71 million, up 8.3 times from ₽8.28 million in the previous year. Revenue increased 119.4% to ₽33.75 million against ₽15.38 million a year earlier.
27.04.2024
Board of Directors of Artgen recommended that dividends be paid for 2023 in the amount of ₽1.2 per ordinary share. The last day of the purchase of securities to receive dividends is June 14, 2024. Dividend yield may amount to 1.07%.
General information
Company nameArtgen
Tags#biotechnology, #pharmacy, #innovations of the russia
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websiteartgen.ru
Information disclosuree-disclosure.ru